Fig. 5

Expression levels of CA9 related gene in MDA-MB-231, BT-549 and MCF-7 cells treated with combination therapy of eribulin and deferoxamine as measured by RT-PCR (a). Eribulin significantly downregulated CA9 expression levels in iron-deficient BT-549 cells by treated with deferoxamine (p = 0.0098). Expression levels of N-cadherin related gene, CDH2 (b) and ZEB1 (c), in MDA-MB-231, BT-549 and MCF-7 cells treated with combination therapy of eribulin and deferoxamine as measured by RT-PCR. Eribulin significantly downregulated CDH2 expression levels in iron-deficient MDA-MB-231 and BT-549 cells by treated with deferoxamine (p = 0.0174, p = 0.0430, respectively), and significantly downregulated ZEB1 expression levels in iron-deficient MDA-MB-231 and MCF-7 cells by treated with deferoxamine (p = 0.0096, p = 0.0267, respectively). Expression levels of PD-L1 related gene in MDA-MB-231, BT-549 and MCF-7 cells treated with combination therapy of eribulin and deferoxamine as measured by RT-PCR (d). Eribulin slightly downregulated CD274 expression levels in iron-deficient MDA-MB-231 and MCF-7 cells by treated with deferoxamine